Hematologic Diseases

Expanding access to hematopoietic stem cell transplants for patients in need

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial
  • BMT Comparative Study

    Phase 3
    0
    I
    II
    III
    IV

    A multi-phase, multi-center clinical trial of partially HLA-mismatched (≥4/8), unrelated bone marrow for transplantation to treat hematologic malignancies (MDS, AML, CLL, ALL, etc.). The study will compare the effectiveness of mismatched Ossium HPC, Marrow to live donor haploidentical transplants.

    Related Products

    HPC, Marrow

    Partners

    NMDP / Be the Match / CIBMTR

  • Micro Bone Marrow Transplants

    Pre-Clinical
    0
    I
    II
    III
    IV

    We are developing a safety and feasibility clinical trial for blood cancers where patients will receive a reduced (‘micro’) conditioning regimen and a mismatched bone marrow transplant using Ossium HPC, Marrow.

    Related Products

    HPC, Marrow

    Partners

    Columbia University


Organ Transplant Rejection

Allowing organ transplant recipients to lead healthy lives without immunosuppression

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial
  • Multivisceral Transplantation

    Phase 1
    0
    I
    II
    III
    IV

    Phase 1 safety and feasibility clinical trial with the objective of inducing tolerance in intestinal transplant patients by establishing mixed Chimerism via infusion of Ossium’s selected CD34+ cells processed from the organ donor's bone marrow.

    Related Products

    Selected CD34+ Cells

    Partners

    Columbia University


Diseases of Inflammation

Modulating immune function and inflammation to treat diseases characterized by the presence of an inflammatory component

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial

Partner with Us

Let's work together to revolutionize treatment for patients suffering from hematologic diseases, organ transplant rejection, and diseases of inflammation.